Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Larimar Therapeutics, Inc. (ZA71.F)

1.9400
0.0000
(0.00%)
As of April 24 at 8:04:42 AM GMT+2. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ZA71.F

Recent News: ZA71.F

View More
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?
Simply Wall St. 27 days ago
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire last month
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
GlobeNewswire last month
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
GlobeNewswire 2 months ago
Bullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of Stock

Bullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of Stock
Simply Wall St. 3 months ago
Larimar Therapeutics announces initial data from OLE study of nomlabofusp

Larimar Therapeutics announces initial data from OLE study of nomlabofusp
TipRanks 4 months ago
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia
GlobeNewswire 4 months ago
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
GlobeNewswire 5 months ago
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
GlobeNewswire 5 months ago
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Simply Wall St. 6 months ago
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
GlobeNewswire 7 months ago
View More

Related Tickers

2BO.F Serina Therapeutics Inc. R
5.10
0.00%
 
2GH.F Merus N.V.
32.60
0.00%
 
PCJ.F Abeona Therapeutics Inc.
4.7200
+5.14%
 
DRUG.CN Bright Minds Biosciences Inc.
47.48
0.00%
 
NEXI NexImmune, Inc.
0.0001
0.00%
 
SER Serina Therapeutics, Inc.
6.09
+5.36%
 
VALN Valneva SE
6.99
+1.75%
 
SION Sionna Therapeutics, Inc.
12.60
-3.74%
 
AARD Aardvark Therapeutics, Inc. Common Stock
8.22
-3.52%
 
KALV KalVista Pharmaceuticals, Inc.
12.88
+3.45%